MSF responds to news that Gavi will release funds from pneumonia vaccine ‘Advance Market Commitment’ to first new product from a developing country manufacturer
*Note: This briefing document offers only a shortlist of priority candidate therapeutics. This document will be updated on a regular basis and may not be completely up to date due to rapid developments. Please refer to the last updated date at the top of the document.
The global COVID-19 pandemic presents an unprecedented public health challenge to all countries in the world. Ensuring the availability and accessibility of effective medicines is one of the vital pillars to support the response and control of the pandemic globally.
To date, multiple clinical trials are ongoing in different countries to test the therapeutic candidates for SARS-CoV-2 infection. This briefing document aims to provide an up-to-date snapshot analysis of the key access and supply challenges for selected promising candidate medicines.
Information in this briefing document:
- Background explanation of the exclusivity barriers that could affect access to COVID-19 therapeutics, including patents, data exclusivity, and policy and legal safeguards.
- Key drug information for selected leading candidates, including medical attributes, patents and other exclusivity rights, supply situation, and pricing.
- Colour-coded summary table of access risk levels for selected drug candidates, related to supply, manufacturing capacity, pricing, intellectual property barriers, and regulatory challenges.
Read, watch, shareAccess Challenges to COVID-19 Therapeutic Candidates > Paragraphs
A new shot at protecting children from pneumonia: will leaders accelerate access for the millions of children left behind?
An estimated 422 million people are living with diabetes worldwide. Prevalence has nearly doubled over the past 30 years and is now rising faster in low- and middle-income countries than in high-income countries.
Diabetes is a chronic, progressive disease that can be controlled with effective treatment. However, in many countries, people living with diabetes are not getting the treatment they need to stay healthy. In fact, only about half of people requiring insulin have access to it.
MSF works in over 70 countries worldwide and in most of these settings, insulin is often not available in public health facilities or private pharmacies. In 20 projects across 11 countries, MSF focuses on diabetes as one of the most common non-communicable diseases (NCDs) in people receiving care in our clinics.
Read, watch, shareA century of neglect: challenges of access to insulin for diabetes care > Paragraphs
After a decade of strong commitments to fight the twin epidemics of HIV and tuberculosis (TB), a decline in international funding and the rapid shifting of the financial burden to affected countries is in danger of reversing lifesaving gains and causing an ‘epidemic rebound’ in some countries. To highlight this reality and the expanding gaps in the HIV and TB responses, MSF produced a report analyzing the financial and systemic challenges in 9 countries where it runs HIV/TB programmes: Central African Republic, Democratic Republic of Congo, Eswatini, Guinea, Kenya, Malawi, Mozambique, Myanmar, Zimbabwe.
Published ahead of the Global Fund’s 6th replenishment conference in Lyon (France, 8-10 October 2019), the report documents how international funding shortfalls and insufficient domestic resources availability are already causing wide-ranging gaps in HIV and TB diagnosis, prevention and care services; stockouts of essential medicines; and are threatening programmes targeting people with specific needs, such as migrants and people with advanced HIV.